Effects of CYP4F2 Polymorphism on Response to Warfarin During Induction Phase: A Prospective, Open-Label, Observational Cohort Study

Clinical Therapeutics

Volumn 34, Issue 4, 2012, Pages 811-823

  Bejarano Achache, Idit ^a,b   Levy, Liran ^a   Mlynarsky, Liat ^a   Bialer, Meir ^b   Muszkat, Mordechai ^a   Caraco, Yoseph ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

3 hydroxy 3 methyl glutaryl coenzyme A reductase inhibitors; CYP4F2; Pharmacogenetics; Statin; Variability; Warfarin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULATION; ARTICLE; BLOOD ANALYSIS; CAUCASIAN; FEMALE; GENETIC ANALYSIS; GENOTYPE; HETEROZYGOTE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BASE SEQUENCE; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; WARFARIN; YOUNG ADULT;

EID: 84859565615     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.02.009     Document Type: Article

References (50)

1. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133:160S-198S.
2. York M., Agarwal A., Ezekowitz M. Physicians' attitudes and the use of oral anticoagulants: surveying the present and envisioning future. J Thromb Thrombolysis 2003, 16:33-37.
3. Hirsh J., Fuster V., Ansell J., Halperin J.L. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003, 107:1692-1711.
4. Landefeld C.S. The spring meetings-are they dying?. N Engl J Med 1993, 328:1645-1647.
5. Garcia D.A., Witt D.M., Hylek E., et al. Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother 2008, 42:979-988.
6. Caraco Y., Blotnick S., Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008, 83:460-470.
7. Pitsiu M., Parker E.M., Aarons L., Rowland M. A Bayesian method based on clotting factor activity for the prediction of maintenance warfarin dosage regimens. Ther Drug Monit 2003, 25:36-40.
8. Lee C., Coleman R.W., Mungall D.R. Effect of using warfarin plasma concentrations in Bayesian forecasting of prothrombin-time response. Clin Pharm 1987, 6:406-412.
9. Sasaki T., Tabuchi H., Higuchi S., Ieiri I. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting. Pharmacogenomics 2009, 10:1257-1266.
10. Wadelius M., Chen L.Y., Eriksson N., et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007, 121:23-34.
11. Aithal G.P., Day C.P., Kesteven P.J., Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353:717-719.
12. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005, 352:2285-2293.
13. Kamali F., Khan T.I., King B.P., et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004, 75:204-212.
14. Scordo M.G., Pengo V., Spina E., et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002, 72:702-710.
15. Aquilante C.L., Langaee T.Y., Lopez L.M., et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006, 79:291-302.
16. Veenstra D.L., Blough D.K., Higashi M.K., et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 2005, 77:353-364.
17. Wadelius M., Chen L.Y., Lindh J.D., et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009, 113:784-792.
18. Takeuchi F., McGinnis R., Bourgeois S., et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009, 5:e1000433.
19. Caldwell M.D., Berg R.L., Zhang K.Q., et al. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 2007, 5:8-16.
20. Kaminsky L.S., Zhang Z.Y. Human P450 metabolism of warfarin. Pharmacol Ther 1997, 73:67-74.
21. D'Andrea G., D'Ambrosio R.L., Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005, 105:645-649.
22. Wadelius M., Chen L.Y., Downes K., et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005, 5:262-270.
23. Geisen C., Watzka M., Sittinger K., et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005, 94:773-779.
24. Li T., Lange L.A., Li X., et al. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 2006, 43:740-744.
25. Stafford D.W. The vitamin K cycle. J Thromb Haemost 2005, 3:1873-1878.
26. Cryder B., Felczak M., Janociak J., et al. Prevalent aetiologies of non-therapeutic warfarin anticoagulation in a network of pharmacist-managed anticoagulation clinics. J Clin Pharm Ther 2011, 36:64-70.
27. Caldwell M.D., Awad T., Johnson J.A., et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008, 111:4106-4112.
28. Cooper G.M., Johnson J.A., Langaee T.Y., et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008, 112:1022-1027.
29. Borgiani P., Ciccacci C., Forte V., et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009, 10:261-266.
30. Pautas E., Moreau C., Gouin-Thibault I., et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 2010, 87:57-64.
31. Zhang J.E., Jorgensen A.L., Alfirevic A., et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics 2009, 19:781-789.
32. Lee M.T., Chen C.H., Chou C.H., et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 2009, 10:1905-1913.
33. Perini J.A., Struchiner C.J., Silva-Assuncao E., Suarez-Kurtz G. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther 2010, 87:417-420.
34. Cavallari L.H., Langaee T.Y., Momary K.M., et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010, 87:459-464.
35. McDonald M.G., Rieder M.J., Nakano M., et al. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 2009, 75:1337-1346.
36. Hsu M.H., Savas U., Griffin K.J., Johnson E.F. Regulation of human cytochrome P450 4F2 expression by sterol regulatory element-binding protein and lovastatin. J Biol Chem 2007, 282:5225-5236.
37. Douketis J.D., Arneklev K., Goldhaber S.Z., et al. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med 2006, 166:853-859.
38. Gage B.F., Fihn S.D., White R.H. Management and dosing of warfarin therapy. Am J Med 2000, 109:481-488.
39. Schwarz U.I., Ritchie M.D., Bradford Y., et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008, 358:999-1008.
40. Storey J.D., Tibshirani R. Statistical significance for genomwide studies. Proc Natl Acad Sci USA 2003, 100:9440-9445.
41. Benjamini Y., Drai D., Elmer G., et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001, 125:279-284.
42. Osman A., Enstrom C., Arbring K., et al. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. J Thromb Haemost 2006, 4:1723-1729.
43. Peyvandi F., Spreafico M., Siboni S.M., et al. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 2004, 75:198-203.
44. Jorgensen A.L., Al-Zubiedi S., Zhang J.E., et al. Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics 2009, 19:800-812.
45. Tie J.K., Stafford D.W. Structure and function of vitamin K epoxide reductase. Vitam Horm 2008, 78:103-130.
46. Cushman M., Booth S.L., Possidente C.J., et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001, 112:572-577.
47. Chimowitz M.I., Lynn M.J., Howlett-Smith H., et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005, 352:1305-1316.
48. Schelleman H., Bilker W.B., Brensinger C.M., et al. Fibrate/statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med 2010, 123:151-157.
49. Sconce E.A., Khan T.I., Daly A.K., et al. The impact of simvastatin on warfarin disposition and dose requirements. J Thromb Haemost 2006, 4:1422-1424.
50. Hirani V., Yarovoy A., Kozeska A., et al. Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies. Arch Biochem Biophys 2008, 478:59-68.